UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

IN RE PHARMACEUTICAL INDUSTRY AVERAGE WHOLESALE PRICE)) MDL No. 1456
LITIGATION) CIVIL ACTION: 01-CV-12257-PBS
THIS DOCUMENT RELATES TO ALL CLASS ACTIONS) Judge Patti B. Saris)

PLAINTIFFS' REPLY TO THE JOHNSON & JOHNSON GROUP'S MEMORANDUM OF LAW IN OPPOSITION TO CLASS CERTIFICATION

[REDACTED VERSION]

Plaintiffs respectfully submit this reply to defendant Johnson & Johnson Group's ("J&J") Memorandum of Law in Opposition to Class Certification.

The primary contention in J&J's "separate" memorandum is that each of its operating companies is "decentralized," and that, as a result, the pricing and marketing practices of the parent and seven operating companies are too highly individualized for class treatment. J&J Br. at 1-2. However, the clear record and well-established law belie J&J's arguments. Plaintiffs can and will use common proof against J&J. It will include proof that each J&J entity published AWPs, the AWPs were artificially inflated, inflation was for the purpose of moving market shares, and as a result class members who paid for J&J drugs were injured. The fact J&J is decentralized does not detract from the core common conduct each J&J entity engaged in.

I. THE CORE ISSUES AS TO J&J'S MISCONDUCT CAN BE ESTABLISHED BY COMMON PROOF

Despite defendants' effort to overcomplicate class certification issues in this case, this is not a case where individualized facts swamp common issues. In its brief, J&J highlights the fact that the case involves thirty-four J&J drugs, manufactured by seven J&J entities, each of which has a different indication and is marketed and sold differently to a variety of customers. J&J Br. at 1, 8. However, the variations identified by J&J are red herrings. The core class-wide issues in this case – whether AWP was the basis for reimbursement, whether J&J deliberately inflated and controlled the AWPs that were published by industry compendia, whether J&J provided substantial undisclosed rebates and administrative fees to PBMs on their oral drugs, and whether the Class was harmed by J&J's misconduct – are present here and can be established by common proof. The


1534.16 0151 MTN.DOC - 1 -

¹ J&J also contends that Dr. Hartman's analysis is illogical and that Plaintiffs' case is unmanageable. J&J Br. at 2, 9-10. Each of these contentions is a mere rehashing of arguments raised in defendants' opening brief and in their motion to strike the testimony of Dr. Hartman. In further response, Plaintiffs incorporate by way of reference the arguments set forth in their Reply Memorandum in Support of Class Certification and Plaintiffs' Opposition to the Motion To Strike.

existence of different business units cannot detract from the common issues created by each unit's adherence to the same AWP scheme.

Plaintiffs can establish through common proof that AWP was the basis for reimbursement for each class member. For the Part B Class, regulations required that drugs were priced and reimbursed based on AWP. As for self-administered and physician administered drugs, defendants' own documents prove beyond any doubt that AWP was the "industry standard," and that "payers use AWP as a basis for reimbursing retail pharmacy." Plaintiffs can prove this industry standard through the introduction of contracts at every level of the distribution chain that uniformly uses AWP as the basis for payment.² Plaintiffs also will introduce expert testimony, based on economic analysis, to show what the price would have been but for the AWP scheme, and the impact of the scheme on the Class on a drug-by-drug basis.


As to J&J, the record is replete with evidence that the J&J companies deliberately inflated the AWPs of their drugs, controlled the prices that were published by compendia, and provided relates and administrative fees to PPMs.




² See Summary charts of contracts produced in this case confirming the ubiquity of AWP, used in the tutorial attached as Exhibits 2-3 to Plaintiffs' Reply Memorandum in Support of Class Certification.

1534.16 0151 MTN.DOC - 2 -

³ All exhibits referenced in this memorandum are attached to the Declaration of Steve W. Berman In Support of Plaintiffs' Reply To Johnson & Johnson Group's Individual Memorandum In Opposition To Class Certification unless otherwise indicated.



1534.16 0151 MTN.DOC - 3 -



The designation of certain fees as "administrative fees" is further evidence of the PBMs and J&J conspiring to hide drug discounts from Class members. Both administrative fees and rebates are typically calculated based on a percentage of total purchases by a PBM's members. However, while a PBM may share some of the rebates it receives with its members, the PBMs never share their administrative fees with members.

Ex. 3. It is to the PBM's benefit to designate some of their payments as administrative fees, as opposed to rebates.


Ex. 12.

Accordingly, Plaintiffs will be able to establish the core issues in its claims against J&J by common proof.

1534.16 0151 MTN.DOC - 4 -

II. THE J&J PARENT COMPANY CENTRALLY CONTROLS PRICING AND DRUG REBATE PAYMENTS

J&J contends that there is no evidence linking the pricing, marketing and sales activity of its operating companies. J&J Br. at p. 1, 8. J&J contends that each of the J&J companies operates independently from its "decentralized" parent company and makes its own decisions. J&J Br. at p. 8. Contrary to this contention, the record shows that the J&J drugs were priced, sold and marketed under company-wide policies and practices.



Second, it is clear that the parent company has been highly involved in overseeing the strategic pricing and marketing of its drugs.

Ex. 5


Ex. 13.

Ex. 13.


Ex. 13.

1534.16 0151 MTN.DOC - 5 -

Janssen's Director of Trade Relations, William Parks, also testified that J&J reviews Janssen's annual business plans and sales reports, and approves product price changes. *See* Parks (Janssen) Tr. at pp. 38-39, 58-59, Ex. 2.



1534.16 0151 MTN.DOC - 6 -



manipulating AWPs is organization-wide and centrally controlled, and defendant's argument at this stage of the case is meritless.

III. CONCLUSION

For the foregoing reasons, Plaintiffs' respectfully request that this Court grant their Motion for Class Certification.

1534.16 0151 MTN.DOC - 7 -

DATED: December 17, 2004.

By /s/ Steve W. Berman

Thomas M. Sobol (BBO#471770) Edward Notargiacomo (BBO#567636) Hagens Berman LLP One Main Street, 4th Floor Cambridge, MA 02142 Telephone: (617) 482-3700 Facsimile: (617) 482-3003

LIAISON COUNSEL

Steve W. Berman Sean R. Matt Hagens Berman LLP 1301 Fifth Avenue, Suite 2900 Seattle, WA 98101 Telephone: (206) 623-7292

Facsimile: (206) 623-0594

Elizabeth Hartweg Fegan Hagens Berman LLP 60 W. Randolph Street, Suite 200 Chicago, IL 60601 Telephone: (312) 762-9235 Facsimile: (312) 762-9286

Jeffrey Kodroff John Macoretta Spector, Roseman & Kodroff, P.C. 1818 Market Street, Suite 2500 Philadelphia, PA 19103 Telephone: (215) 496-0300

Facsimile: (215) 496-6611

Samuel D. Heins Alan I. Gilbert Brian L. Williams Susan E. MacMenamin Heins, Mills & Olson, P.C. 3550 IDS Center 80 South Eighth Street Minneapolis, MN 55402 Telephone: (612) 338-4605

Facsimile: (612) 338-4692

- 8 -1534.16 0151 MTN.DOC

CHAIRS OF LEAD COUNSEL COMMITTEE

Marc H. Edelson Allan Hoffman Hoffman & Edelson 45 West Court Street Doylestown, PA 18901 Telephone: (215) 230-8043 Facsimile: (215) 230-8735

Kenneth A. Wexler Jennifer F. Connolly The Wexler Firm One North LaSalle Street, Suite 2000 Chicago, IL 60602 Telephone: (312) 346-2222 Facsimile: (312) 346-0022

MEMBERS OF LEAD COUNSEL COMMITTEE AND EXECUTIVE COMMITTEE

1534.16 0151 MTN.DOC - 9 -

CERTIFICATE OF SERVICE

I hereby certify that I, Steve W. Berman, an attorney, caused a true and correct copy of the foregoing **PLAINTIFFS' REPLY TO THE JOHNSON & JOHNSON GROUP'S MEMORANDUM OF LAW IN OPPOSITION TO CLASS CERTIFICATION** to be electronically filed with the Court pursuant to the December 16, 2004 Order and to be delivered to all counsel of record by electronic service pursuant to Paragraph 11 of the Case Management Order No. 2, by sending on December 17, 2004 a copy to Verilaw Technologies for posting and notification to all parties.

By /s/ Steve W. Berman
Steve W. Berman
HAGENS BERMAN LLP
1301 Fifth Avenue, Suite 2900
Seattle, WA 98101
(206) 623-7292

1534.16 0151 MTN.DOC - 10 -